A citation-based method for searching scientific literature

Anja Vogt. Clin Res Cardiol Suppl 2019
Times Cited: 8







List of co-cited articles
43 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
297
62

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Nicholas J Viney, Julian C van Capelleveen, Richard S Geary, Shuting Xia, Joseph A Tami, Rosie Z Yu, Santica M Marcovina, Steven G Hughes, Mark J Graham, Rosanne M Crooke,[...]. Lancet 2016
427
50

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
Robert Clarke, John F Peden, Jemma C Hopewell, Theodosios Kyriakou, Anuj Goel, Simon C Heath, Sarah Parish, Simona Barlera, Maria Grazia Franzosi, Stephan Rust,[...]. N Engl J Med 2009
892
50

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Peter Willeit, Paul M Ridker, Paul J Nestel, John Simes, Andrew M Tonkin, Terje R Pedersen, Gregory G Schwartz, Anders G Olsson, Helen M Colhoun, Florian Kronenberg,[...]. Lancet 2018
212
50

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
50

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Sotirios Tsimikas, Nicholas J Viney, Steven G Hughes, Walter Singleton, Mark J Graham, Brenda F Baker, Jennifer L Burkey, Qingqing Yang, Santica M Marcovina, Richard S Geary,[...]. Lancet 2015
309
37


Lipoprotein(a) as a cardiovascular risk factor: current status.
Børge G Nordestgaard, M John Chapman, Kausik Ray, Jan Borén, Felicita Andreotti, Gerald F Watts, Henry Ginsberg, Pierre Amarenco, Alberico Catapano, Olivier S Descamps,[...]. Eur Heart J 2010
37

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Eberhard Roeseler, Ulrich Julius, Franz Heigl, Ralf Spitthoever, Dennis Heutling, Paul Breitenberger, Josef Leebmann, Walter Lehmacher, Pia R Kamstrup, Børge G Nordestgaard,[...]. Arterioscler Thromb Vasc Biol 2016
115
37

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.
Don P Wilson, Terry A Jacobson, Peter H Jones, Marlys L Koschinsky, Catherine J McNeal, Børge G Nordestgaard, Carl E Orringer. J Clin Lipidol 2019
169
37

High lipoprotein(a) and high risk of mortality.
Anne Langsted, Pia R Kamstrup, Børge G Nordestgaard. Eur Heart J 2019
91
37

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Lotte C A Stiekema, Erik S G Stroes, Simone L Verweij, Helina Kassahun, Lisa Chen, Scott M Wasserman, Marc S Sabatine, Venkatesh Mani, Zahi A Fayad. Eur Heart J 2019
69
37

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Gerald F Watts, Dick C Chan, Ransi Somaratne, Scott M Wasserman, Rob Scott, Santica M Marcovina, P Hugh R Barrett. Eur Heart J 2018
82
37

Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.
Christoph Waldeyer, Nataliya Makarova, Tanja Zeller, Renate B Schnabel, Fabian J Brunner, Torben Jørgensen, Allan Linneberg, Teemu Niiranen, Veikko Salomaa, Pekka Jousilahti,[...]. Eur Heart J 2017
104
37

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
Pia R Kamstrup, Anne Tybjaerg-Hansen, Rolf Steffensen, Børge G Nordestgaard. JAMA 2009
758
37

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
37

PCSK9 inhibitors: A new era of lipid lowering therapy.
Rahul Chaudhary, Jalaj Garg, Neeraj Shah, Andrew Sumner. World J Cardiol 2017
126
25

A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.
K BERG. Acta Pathol Microbiol Scand 1963
25

Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.
Pia R Kamstrup, Anne Tybjærg-Hansen, Børge G Nordestgaard. J Am Coll Cardiol 2014
305
25

Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.
Nicolas Perrot, Rutger Verbeek, Manjinder Sandhu, S Matthijs Boekholdt, G Kees Hovingh, Nicholas J Wareham, Kay-Tee Khaw, Benoit J Arsenault. Atherosclerosis 2017
39
25

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Gisle Langslet, Harold Bays, Dirk Blom, Mats Eriksson, Ricardo Dent, Scott M Wasserman,[...]. J Am Coll Cardiol 2014
256
25

Genetic associations with valvular calcification and aortic stenosis.
George Thanassoulis, Catherine Y Campbell, David S Owens, J Gustav Smith, Albert V Smith, Gina M Peloso, Kathleen F Kerr, Sonali Pechlivanis, Matthew J Budoff, Tamara B Harris,[...]. N Engl J Med 2013
556
25

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.
Claes Bergmark, Asheesh Dewan, Alexina Orsoni, Esther Merki, Elizabeth R Miller, Min-Jeong Shin, Christoph J Binder, Sohvi Hörkkö, Ronald M Krauss, M John Chapman,[...]. J Lipid Res 2008
208
25

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Eur Heart J 2016
25

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.
Guillaume Paré, Artuela Çaku, Matthew McQueen, Sonia S Anand, Enas Enas, Robert Clarke, Michael B Boffa, Marlys Koschinsky, Xingyu Wang, Salim Yusuf. Circulation 2019
110
25

Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.
Rutger Verbeek, Renate M Hoogeveen, Anne Langsted, Lotte C A Stiekema, Simone L Verweij, G Kees Hovingh, Nicholas J Wareham, Kay-Tee Khaw, S Matthijs Boekholdt, Børge G Nordestgaard,[...]. Eur Heart J 2018
66
25

Lipoprotein(a): the revenant.
Baris Gencer, Florian Kronenberg, Erik S Stroes, François Mach. Eur Heart J 2017
88
25

Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.
Fleur M van der Valk, Siroon Bekkering, Jeffrey Kroon, Calvin Yeang, Jan Van den Bossche, Jaap D van Buul, Amir Ravandi, Aart J Nederveen, Hein J Verberne, Corey Scipione,[...]. Circulation 2016
252
25


Lipoprotein (a) measurements for clinical application.
Santica M Marcovina, John J Albers. J Lipid Res 2016
146
25


Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Stephen Burgess, Brian A Ference, James R Staley, Daniel F Freitag, Amy M Mason, Sune F Nielsen, Peter Willeit, Robin Young, Praveen Surendran, Savita Karthikeyan,[...]. JAMA Cardiol 2018
248
25

Screening for High Lipoprotein(a).
George Thanassoulis. Circulation 2019
16
25

Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays.
Hubert Scharnagl, Tatjana Stojakovic, Benjamin Dieplinger, Hans Dieplinger, Gertraud Erhart, Gerhard M Kostner, Markus Herrmann, Winfried März, Tanja B Grammer. Atherosclerosis 2019
40
25


Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
Thomas M Stulnig, Claudia Morozzi, Roman Reindl-Schwaighofer, Claudia Stefanutti. Curr Atheroscler Rep 2019
11
25

Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.
Sebhat Erqou, Alexander Thompson, Emanuele Di Angelantonio, Danish Saleheen, Stephen Kaptoge, Santica Marcovina, John Danesh. J Am Coll Cardiol 2010
212
25

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera A Bittner, Michael Szarek, Philip E Aylward, Deepak L Bhatt, Rafael Diaz, Jay M Edelberg, Zlatko Fras, Shaun G Goodman, Sigrun Halvorsen, Corinne Hanotin,[...]. J Am Coll Cardiol 2020
158
25


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
25

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
25

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, Jean-Claude Tardif, Seth J Baum, Elizabeth Steinhagen-Thiessen, Michael D Shapiro, Erik S Stroes, Patrick M Moriarty, Børge G Nordestgaard,[...]. N Engl J Med 2020
285
25

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren,[...]. N Engl J Med 2017
458
25



Role of Noncanonical Wnt Signaling Pathway in Human Aortic Valve Calcification.
Isabella Albanese, Bin Yu, Hamood Al-Kindi, Bianca Barratt, Leah Ott, Mohammad Al-Refai, Benoit de Varennes, Dominique Shum-Tim, Marta Cerruti, Ophélie Gourgas,[...]. Arterioscler Thromb Vasc Biol 2017
47
12

Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes.
M A Austin, C Sandholzer, J V Selby, B Newman, R M Krauss, G Utermann. Am J Hum Genet 1992
94
12

Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve.
Salah A Mohamed, Zouhair Aherrahrou, Henrike Liptau, Armin W Erasmi, Carolin Hagemann, Sandra Wrobel, Katja Borzym, Heribert Schunkert, Hans H Sievers, Jeanette Erdmann. Biochem Biophys Res Commun 2006
156
12

Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression.
Tripti Gaur, Christopher J Lengner, Hayk Hovhannisyan, Ramesh A Bhat, Peter V N Bodine, Barry S Komm, Amjad Javed, Andre J van Wijnen, Janet L Stein, Gary S Stein,[...]. J Biol Chem 2005
804
12

Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions.
Xin Zeng, He Huang, Keiko Tamai, Xinjun Zhang, Yuko Harada, Chika Yokota, Karla Almeida, Jianbo Wang, Brad Doble, Jim Woodgett,[...]. Development 2008
327
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.